WebSep 18, 2024 · RELATIVITY-047 is the first global randomized, double-blind, phase 2/3 registrational study to evaluate the combination of LAG-3 and PD-1 inhibition with relatlimab and nivolumab as a novel fixed-dose combination vs nivolumab alone in patients with previously untreated metastatic or unresectable melanoma. WebMar 20, 2024 · A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma (RELATIVITY-047) ... Other Study ID Numbers: …
LAG3 inhibitors are changing the landscape of immunotherapy
WebApr 10, 2024 · We just published in Nature [results of a] neoadjuvant study where the response rate in our neoadjuvant patients was 57%, so the earlier you use it, the more signaling happens through TCR, and the more you can modulate anti-LAG3. 4 Now, the RELATIVITY-047 study [NCT03470922] was a phase 3 trial followed by the FDA approval … WebOct 17, 2024 · A main study involving 714 patients with previously untreated advanced melanoma showed that Opdualag was effective at slowing the worsening of the disease in those patients whose cancer produced a low level amount of PD-L1.. Patients with low levels of PD-L1 (<1%) who had Opdualag treatment lived for 6.7 months without their disease … iowa state third party login
Bristol Myers Squibb Announces RELATIVITY-047, a Trial …
WebMay 19, 2024 · Findings from the RELATIVITY-047 study will be presented during the Melanoma/Skin Cancers Oral Abstract Session on Sunday, June 6, 2024, 8:00am-11:00am ET. The study is included in the ASCO Press Program. Other key research shows new treatments and diagnostic advances in lung cancer, leukemia, head and neck cancer, … WebMar 26, 2024 · RELATIVITY-047 is a randomized, double-blind phase 2/3 study that looked at 714 patients with previously untreated metastatic or unresectable melanoma who were … WebJan 10, 2024 · In an accompanied editorial, Adam E. Frampton and Shivan Sivakumar stated that as the data from the RELATIVITY-047 study mature, if the survival benefit of … iowa state ticketmaster login